JF
CHRS icon

Jump Financial’s Coherus Oncology CHRS Stock Holding History

Jump Financial’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-33,267
Closed -$111K – 1931
2023
Q4 		$111K Buy
33,267
+11,180
+51% +$29.9K ﹤0.01% 1652
2023
Q3 		$82.6K Sell
22,087
-74,399
-77% -$344K ﹤0.01% 1703
2023
Q2 		$412K Buy
96,486
+82,560
+593% +$487K 0.02% 1127
2023
Q1 		$95.3K Buy
+13,926
New +$108K ﹤0.01% 1443
2022
Q3 		– Sell
-47,801
Closed -$346K – 1633
2022
Q2 		$346K Buy
+47,801
New +$416K 0.01% 1008
2021
Q4 		– Sell
-17,127
Closed -$275K – 1416
2021
Q3 		$275K Sell
17,127
-6,773
-28% -$99.3K 0.02% 700
2021
Q2 		$331K Buy
+23,900
New +$338K 0.03% 627

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Jump Financial's CHRS Position: Q1 2024 in Review

Jump Financial sold out of Coherus Oncology (CHRS) in Q1 2024, closing a stake of 33,267 shares — an estimated $111K sold.

Jump Financial first reported a position in CHRS in Q2 2021 and held it in 7 quarters. The position peaked at $412K in Q2 2023. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.

  • Jump Financial reported no remaining Coherus Oncology position as of Q1 2024 after selling out during the quarter.
  • Jump Financial sold 33,267 Coherus Oncology shares in Q1 2024, an estimated $111K.
  • Jump Financial first reported a position in Coherus Oncology in Q2 2021 and held it in 7 quarters.
  • Jump Financial's Coherus Oncology position peaked at $412K in Q2 2023.
  • 137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.

Based on Jump Financial's 13F filing for Q1 2024, filed 13 May 2024.